BioCryst launches Phase 1 trial for FOP

The IFOPA is pleased to share this news from BioCryst Pharmaceuticals about the launch of their Phase 1 First-in-Humans trial for BCX9250, an oral ALK-2 Inhibitor for FOP. Visit BioCryst's website to learn more.